Abstract
Cholangiocarcinomas (CCAs) are a heterogenous group of cancers arising from the biliary epithelium. CCAs tend to metastasize with early lymph node involvement lending to poor surgical outcomes and need for systemic therapy. Given the paucity of successful therapies in these cancers, it is important to understand the molecular drivers and to develop therapeutic strategies using targeted therapies either alone or in combination. The molecular landscape offers several new potentially targetable drivers.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 9-15 |
| Number of pages | 7 |
| Journal | European Oncology and Haematology |
| Volume | 18 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2022 |
Keywords
- Cholangiocarcinoma
- fibroblast growth factor receptors (FGFR)
- immune therapy
- intrahepatic cholangiocarcinoma (iCCA)
- isocitrate dehydrogenase (IDH)
- molecular testing
ASJC Scopus subject areas
- Hematology
- Oncology